Valuation: Verastem, Inc.

Market Cap 650M 561M 527M 480M 902M 62.17B 914M 6.17B 2.42B 31.15B 2.44B 2.39B 104B P/E 2026 *
-4.48x
P/E 2027 * -6.16x
Enterprise Value 692M 598M 561M 511M 960M 66.18B 973M 6.57B 2.58B 33.16B 2.6B 2.54B 110B EV / Sales 2026 *
5.94x
EV / Sales 2027 * 3.59x
Free-Float
99.1%
Yield 2026 *
-
Yield 2027 * -
1 day+9.12%
1 week+5.74%
Current month+23.79%
1 month+19.07%
3 months+66.20%
6 months+22.53%
Current year-6.99%
1 week 6.44
Extreme 6.44
7.2
1 month 5.54
Extreme 5.54
7.2
Current year 3.43
Extreme 3.43
8.88
1 year 3.43
Extreme 3.43
11.24
3 years 2.1
Extreme 2.1
14.22
5 years 2.1
Extreme 2.1
42.96
10 years 2.1
Extreme 2.1
124.2
Manager TitleAgeSince
Chief Executive Officer 65 01/08/2023
Director of Finance/CFO 39 31/10/2022
Chief Tech/Sci/R&D Officer - 18/04/2024
Director TitleAgeSince
Chairman 62 -
Director/Board Member 65 01/08/2023
Director/Board Member 69 03/05/2017
Date Insider Type Main position Quantity % Market Cap.
3/8/26 Sell

Chief Executive Officer

-1,302 0.0021%
21/5/26 Free

Chairman

36,000 0.0410%
21/5/26 Free

Director

36,000 0.0410%
Change 5-day change 1-year change 3-year change Capi.($)
+9.12%+5.74%-12.65%-26.66% 650M
+4.80%+3.44%+70.64%+109.32% 73.25B
-0.87%+13.32%+48.03%+89.17% 61.95B
+3.70%-4.77%+0.41%+484.07% 28.02B
+5.24%+5.65%+56.71%+21.30% 24.15B
-1.60%-1.29%-19.31%-19.10% 23.01B
-6.00%+6.02%+244.39%+430.80% 18.35B
+1.00%+6.72%+41.09%-13.36% 19.46B
+3.83%+2.65%+21.42%+557.58% 15.92B
+2.11%-1.21%+36.57%+149.14% 12.96B
Average +2.15%+1.53%+48.73%+178.23% 27.77B
Weighted average by Cap. +1.81%+3.14%+54.65%+164.22%

Financials

2026 *2027 *
Net sales 116M 101M 94.31M 85.9M 162M 11.13B 164M 1.11B 433M 5.58B 437M 428M 18.55B 181M 156M 147M 134M 251M 17.32B 255M 1.72B 674M 8.68B 680M 665M 28.86B
Net income -166M -143M -134M -122M -230M -15.86B -233M -1.57B -617M -7.95B -623M -609M -26.43B -157M -136M -127M -116M -218M -15.02B -221M -1.49B -584M -7.52B -590M -577M -25.03B
Net Debt 41.9M 36.17M 33.94M 30.91M 58.12M 4.01B 58.92M 398M 156M 2.01B 157M 154M 6.68B -
Logo Verastem, Inc.
Verastem, Inc. is a late-stage development biopharmaceutical company, which focuses on the development and commercialization of new medicines to improve the lives of patients diagnosed with ras sarcoma (RAS)/ mitogen-activated pathway kinase (MAPK) pathway-driven cancers. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation.
Employees
102
Date Price Change Volume
17/08/26 USD 7.180 +9.12% 2,284,012
14/08/26 USD 6.580 -1.35% 1,280,177
13/08/26 USD 6.670 -4.03% 1,856,897
12/08/26 USD 6.950 -1.42% 1,263,817
11/08/26 USD 7.050 +3.83% 2,087,689
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
7.180USD
Average target price
14.75USD
Spread / Average Target
+105.43%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VSTM Stock